ArticleJournal of animal science2025
Combined supplementation of essential oils, Saccharomyces cerevisiae and isomaltooligosaccharides improves intestinal absorption and immune functions in weaned piglets.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of composite probiotics on growth performance, diarrhea rate, and serum indicators in newborn Holstein calves.Animal bioscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study evaluated the synergistic effects of essential oils (EOs), Saccharomyces cerevisiae (SC), and isomaltooligosaccharides (IMO) on intestinal health and systemic immunity in weaned piglets using a randomized block design across two commercial farms. Within each farm, 108 piglets weaned at 24 d of age were randomly divided into 3 groups (3 pens per group, 12 piglets per pen). The piglets were fed a basal diet (CON) and a basal diet supplemented with antibiotics (0.5 kg/t colistin sulfate + 0.5 kg/t tilmicosin) (ANTI) or additive mixture (0.1 kg/t EOs, 0.3 kg/t SC and 1 kg/t IMO) (ESI) for 28 days. The results showed that both ESI and ANTI treatments significantly increased the ratio of villus height to crypt depth (P < 0.05). Specifically, ESI supplementation elevated serum IgA, hepatic IgA, and jejunal mucosal sIgA levels (P < 0.05), while upregulating hepatic IL1B, IL2, IL6, and IFNG expression alongside jejunal mucosal IL1B, IL6, and PPARG expression-contrasting with its downregulation of jejunal mucosal IFNG mRNA (P < 0.05). Conversely, compared with the CON group, ANTI supplementation increased serum IgA level and jejunal mucosal concentrations of sIgA, IgG, IgM, IFN-γ, and IL-10, while also upregulating jejunal mucosal gene expression of IGF1 and TGFB1 (P < 0.05). In addition, compared with Farm I, piglets at Farm II exhibited higher jejunal pH, elevated serum levels of IgA and IL-1β, and upregulated gene expression of IL1B, IL2, IL6, and IFNG in the liver as well as TGFB1, IL1B, IL6, and PPARG in the jejunal mucosa (P < 0.05). Moreover, the robust diet × farm interaction effects on immune gene expression in the liver (IL1B, IL2, and IL6) and jejunal mucosa (IL1B, IL2, IL6, IFNG, IL10, and PPARG) were observed (P < 0.05). Collectively, ESI improved jejunal epithelial maturation, nutrient absorption, and immune function in weaned piglets, with efficacy partly dependent on farm environmental conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.